Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Tuberculosis

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 276 articles:
HTML format



Single Articles


    April 2021
  1. HWANG H, Kang H, Kwon YS, Jeon D, et al
    Outcomes of multidrug-resistant tuberculosis treated with bedaquiline or delamanid.
    Clin Infect Dis. 2021 Apr 10. pii: 6219782. doi: 10.1093.
    PubMed     Abstract available


    March 2021
  2. BALIASHVILI D, Gandhi NR, Kim S, Hughes M, et al
    Resistance to Mycobacterium tuberculosis infection among household contacts: a multinational study.
    Clin Infect Dis. 2021 Mar 27. pii: 6193424. doi: 10.1093.
    PubMed     Abstract available


  3. ADU-GYAMFI C, Savulescu D, Mikhathani L, Otwombe K, et al
    Plasma kynurenine-to-tryptophan ratio, a highly sensitive blood-based diagnostic tool for Tuberculosis in HIV-infected pregnant women.
    Clin Infect Dis. 2021 Mar 15. pii: 6170938. doi: 10.1093.
    PubMed     Abstract available


  4. HUANG HL, Huang WC, Lin KD, Liu SS, et al
    Completion Rate and Safety of Programmatic Screening and Treatment for Latent Tuberculosis Infection in Elderly Patients with Poorly Controlled Diabetic Mellitus: A Prospective Multicenter Study.
    Clin Infect Dis. 2021 Mar 3. pii: 6157057. doi: 10.1093.
    PubMed     Abstract available


    February 2021
  5. BURKE RM, Gupta Wright A
    Diagnosing tuberculosis in people with advanced HIV: more is needed.
    Clin Infect Dis. 2021 Feb 26. pii: 6152006. doi: 10.1093.
    PubMed    


  6. ACHARYA MP, Pradeep SP, Murthy VS, Chikkannaiah P, et al
    CD38 +CD27 -TNF-alpha + on Mtb-specific CD4 + T is a robust biomarker for tuberculosis diagnosis.
    Clin Infect Dis. 2021 Feb 19. pii: 6144985. doi: 10.1093.
    PubMed     Abstract available


  7. DU PREEZ K, Osman M, Seddon JA, Naidoo P, et al
    The impact of the evolving HIV response on the epidemiology of tuberculosis in South African children and adolescents.
    Clin Infect Dis. 2021 Feb 3. pii: 6127007. doi: 10.1093.
    PubMed     Abstract available


    January 2021
  8. GUNASEKERA KS, Walters E, van der Zalm MM, Palmer M, et al
    Development of a treatment-decision algorithm for HIV-uninfected children evaluated for pulmonary tuberculosis.
    Clin Infect Dis. 2021 Jan 15. pii: 6101512. doi: 10.1093.
    PubMed     Abstract available


  9. HUAMAN MA, De Cecco CN, Bittencourt MS, Ticona E, et al
    Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda.
    Clin Infect Dis. 2021 Jan 3. pii: 6060062. doi: 10.1093/cid/ciaa1934.
    PubMed     Abstract available


    December 2020
  10. TACK I, Dumicho A, Ohler L, Shigayeva A, et al
    Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high HIV burden rural South Africa: a retrospective cohort analysis.
    Clin Infect Dis. 2020 Dec 29. pii: 6054965. doi: 10.1093/cid/ciaa1894.
    PubMed     Abstract available


  11. YUEN CM, Majidulla A, Jaswal M, Safdar N, et al
    Cost of delivering 12-dose isoniazid and rifapentine versus 6 months of isoniazid for tuberculosis infection in a high-burden setting.
    Clin Infect Dis. 2020 Dec 8. pii: 6025518. doi: 10.1093/cid/ciaa1835.
    PubMed     Abstract available


  12. OH CE, Ortiz-Brizuela E, Bastos ML, Menzies D, et al
    Comparing the Diagnostic Performance of QFT-Plus to Other Tests of Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.
    Clin Infect Dis. 2020 Dec 8. pii: 6026460. doi: 10.1093/cid/ciaa1822.
    PubMed     Abstract available


  13. KENDALL EA, Kitonsa PJ, Nalutaaya A, Kamoga CE, et al
    The spectrum of tuberculosis disease in an urban Ugandan community and its health facilities.
    Clin Infect Dis. 2020 Dec 6. pii: 6024999. doi: 10.1093/cid/ciaa1824.
    PubMed     Abstract available


  14. WONG EB
    It is time to focus on asymptomatic tuberculosis.
    Clin Infect Dis. 2020 Dec 6. pii: 6024996. doi: 10.1093/cid/ciaa1827.
    PubMed    


  15. VAN TOORN R, Solomons RS, Seddon JA, Schoeman JF, et al
    Thalidomide use for complicated central nervous system tuberculosis in children: insights from an observational cohort.
    Clin Infect Dis. 2020 Dec 6. pii: 6024997. doi: 10.1093/cid/ciaa1826.
    PubMed     Abstract available


    November 2020
  16. ASABOR EN, Vermund SH
    Confronting structural racism in the prevention and control of tuberculosis in the United States.
    Clin Infect Dis. 2020 Nov 26. pii: 6006871. doi: 10.1093/cid/ciaa1763.
    PubMed     Abstract available


  17. HUANG HL, Lee MR, Cheng MH, Lu PL, et al
    Impact of age on outcome of rifapentine-based weekly therapy for latent tuberculosis infection.
    Clin Infect Dis. 2020 Nov 19. pii: 5992466. doi: 10.1093/cid/ciaa1741.
    PubMed     Abstract available


  18. REDDY KP, Denkinger CM, Broger T, McCann NC, et al
    Cost-effectiveness of a novel lipoarabinomannan test for tuberculosis in patients with HIV.
    Clin Infect Dis. 2020 Nov 17. pii: 5983890. doi: 10.1093/cid/ciaa1698.
    PubMed     Abstract available


  19. MONTEPIEDRA G, Kim S, Weinberg A, Theron G, et al
    Using a composite maternal-infant outcome measure in tuberculosis prevention studies among pregnant women.
    Clin Infect Dis. 2020 Nov 4. pii: 5955952. doi: 10.1093/cid/ciaa1674.
    PubMed     Abstract available


  20. COLLINS JM, Stout JE, Ayers T, Hill AN, et al
    Prevalence of Latent Tuberculosis Infection among Non-U.S.-Born Persons by Country of Birth - United States, 2012-2017.
    Clin Infect Dis. 2020 Nov 2. pii: 5952274. doi: 10.1093/cid/ciaa1662.
    PubMed     Abstract available


    October 2020
  21. CEGIELSKI JP, Chan PC, Lan Z, Udwadia ZF, et al
    Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016.
    Clin Infect Dis. 2020 Oct 30. pii: 5943503. doi: 10.1093.
    PubMed     Abstract available


  22. ZHENG X, Bao Z, Forsman LD, Hu Y, et al
    Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response.
    Clin Infect Dis. 2020 Oct 18. pii: 5929670. doi: 10.1093/cid/ciaa1569.
    PubMed     Abstract available


  23. KAKAIRE R, Kiwanuka N, Zalwango S, Sekandi JN, et al
    Excess Risk of Tuberculous Infection among Extra-Household Contacts of Tuberculosis Cases in an African City.
    Clin Infect Dis. 2020 Oct 16. pii: 5925052. doi: 10.1093/cid/ciaa1556.
    PubMed     Abstract available


  24. DUFFY D, Nemes E, Llibre A, Rouilly V, et al
    Immune profiling enables stratification of patients with active TB disease or M. tuberculosis infection.
    Clin Infect Dis. 2020 Oct 16. pii: 5924452. doi: 10.1093/cid/ciaa1562.
    PubMed     Abstract available


  25. ZELNICK JR, Daftary A, Hwang C, Labar AS, et al
    Electronic dose monitoring identifies a high-risk subpopulation in the treatment of drug-resistant tuberculosis and HIV.
    Clin Infect Dis. 2020 Oct 14. pii: 5923372. doi: 10.1093/cid/ciaa1557.
    PubMed     Abstract available


  26. KUHLIN J, Davies Forsman L, Mansjo M, Jonsson Nordvall M, et al
    Genotypic resistance of pyrazinamide but not MIC is associated with longer time to sputum culture conversion in patients with multidrug-resistant tuberculosis.
    Clin Infect Dis. 2020 Oct 3. pii: 5917759. doi: 10.1093/cid/ciaa1509.
    PubMed     Abstract available


    September 2020
  27. CHIDAMBARAM V, Gupte A, Wang JY, Golub JE, et al
    The Impact of Hypertension and Use of Calcium Channel Blockers on Tuberculosis Treatment Outcomes.
    Clin Infect Dis. 2020 Sep 24. pii: 5911212. doi: 10.1093/cid/ciaa1446.
    PubMed     Abstract available


  28. FRASCELLA B, Richards AS, Sossen B, Emery JC, et al
    Subclinical tuberculosis disease - a review and analysis of prevalence surveys to inform definitions, burden, associations and screening methodology.
    Clin Infect Dis. 2020 Sep 16. pii: 5906549. doi: 10.1093/cid/ciaa1402.
    PubMed     Abstract available


  29. DOOKIE N, Padayatchi N, Naidoo K
    Tuberculosis Elimination in the Era of COVID-19: A Moving Target.
    Clin Infect Dis. 2020 Sep 14. pii: 5905579. doi: 10.1093/cid/ciaa1400.
    PubMed    


  30. HAAS MK, Aiona K, Erlandson KM, Belknap RW, et al
    Higher Completion Rates with Self-administered Once-weekly Isoniazid-Rifapentine versus Daily Rifampin in Adults with Latent Tuberculosis.
    Clin Infect Dis. 2020 Sep 11. pii: 5904201. doi: 10.1093/cid/ciaa1364.
    PubMed     Abstract available


    August 2020
  31. LIU Q, Lu P, Shen Y, Li C, et al
    Collateral Impact of the Covid-19 Pandemic on Tuberculosis Control in Jiangsu Province, China.
    Clin Infect Dis. 2020 Aug 28. pii: 5898659. doi: 10.1093/cid/ciaa1289.
    PubMed     Abstract available


  32. PASIPANODYA J, Gumbo T
    The relationship between drug concentration in tuberculosis lesions, epithelial lining fluid, and clinical outcomes.
    Clin Infect Dis. 2020 Aug 28. pii: 5898607. doi: 10.1093/cid/ciaa1271.
    PubMed    


  33. MCCALLUM AD, Pertinez HE, Else LJ, Dilly-Penchala S, et al
    Intrapulmonary pharmacokinetics of first-line anti-TB drugs in Malawian tuberculosis patients.
    Clin Infect Dis. 2020 Aug 28. pii: 5898506. doi: 10.1093/cid/ciaa1265.
    PubMed     Abstract available


  34. MOOSA MS, Maartens G, Gunter H, Allie S, et al
    A Randomized Controlled Trial of Intravenous N-acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury.
    Clin Infect Dis. 2020 Aug 26. pii: 5897464. doi: 10.1093/cid/ciaa1255.
    PubMed     Abstract available


  35. ROMANOWSKI K, Sobkowiak B, Guthrie JL, Cook VJ, et al
    Using Whole Genome Sequencing to Determine the Timing of Secondary Tuberculosis in British Columbia, Canada.
    Clin Infect Dis. 2020 Aug 19. pii: 5894147. doi: 10.1093/cid/ciaa1224.
    PubMed     Abstract available


  36. CAMPBELL JR, Al-Jahdali H, Bah B, Belo M, et al
    Safety and Efficacy of Rifampin or Isoniazid Among People with Mycobacterium tuberculosis Infection and Living with HIV or Other Health Conditions: Post-Hoc Analysis of Two Randomized Trials.
    Clin Infect Dis. 2020 Aug 12. pii: 5891810. doi: 10.1093/cid/ciaa1169.
    PubMed     Abstract available


  37. MARTINEZ L, Woldu H, Chen C, Hallowell BD, et al
    Transmission Dynamics in Tuberculosis Patients with Human Immunodeficiency Virus: A Systematic Review and Meta-Analysis of 32 Observational Studies.
    Clin Infect Dis. 2020 Aug 8. pii: 5889983. doi: 10.1093/cid/ciaa1146.
    PubMed     Abstract available


  38. KUMAR NP, Moideen K, Nancy A, Viswanathan V, et al
    Plasma chemokines are baseline predictors of unfavorable treatment outcomes in pulmonary tuberculosis.
    Clin Infect Dis. 2020 Aug 7. pii: 5885172. doi: 10.1093/cid/ciaa1104.
    PubMed     Abstract available


  39. RAGONNET R, Flegg JA, Brilleman SL, Tiemersma EW, et al
    Revisiting the Natural History of Pulmonary Tuberculosis: a Bayesian Estimation of Natural Recovery and Mortality rates.
    Clin Infect Dis. 2020 Aug 7. pii: 5882189. doi: 10.1093.
    PubMed     Abstract available


  40. NICOL MP, Schumacher SG, Workman L, Broger T, et al
    Accuracy of a novel urine test, Fujifilm SILVAMP TB LAM, for the diagnosis of pulmonary tuberculosis in children.
    Clin Infect Dis. 2020 Aug 6. pii: 5881994. doi: 10.1093/cid/ciaa1052.
    PubMed     Abstract available


  41. PETTIT AC, Stout JE, Belknap R, Benson CA, et al
    Optimal testing choice and diagnostic strategies for latent tuberculosis infection among U.S.-born people living with HIV.
    Clin Infect Dis. 2020 Aug 6. pii: 5881730. doi: 10.1093/cid/ciaa1135.
    PubMed     Abstract available


    July 2020
  42. YOSHIYAMA T, Mitarai S, Takaki A, Aono A, et al
    Multi-drug resistant tuberculosis with simultaneously acquired-drug resistance to bedaquiline and delamanid.
    Clin Infect Dis. 2020 Jul 30. pii: 5879015. doi: 10.1093/cid/ciaa1064.
    PubMed     Abstract available


  43. WEINBERG A, Aaron L, Montepiedra G, Sterling TR, et al
    Effects of Pregnancy and Isoniazid Preventive Therapy on M. tuberculosis Interferon Gamma Response Assays in Women with HIV.
    Clin Infect Dis. 2020 Jul 28. pii: 5877271. doi: 10.1093/cid/ciaa1083.
    PubMed     Abstract available


  44. LIU Y, Gao M, Du J, Wang L, et al
    Reduced susceptibility of Mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China.
    Clin Infect Dis. 2020 Jul 15. pii: 5871905. doi: 10.1093/cid/ciaa1002.
    PubMed     Abstract available


  45. MIRANDA C, Bark CM
    TB, or not TB, the Choice Is Ours.
    Clin Infect Dis. 2020;71:291-292.
    PubMed    


  46. BOLD TD, Cheng MP, Marty FM
    Reply to Singh.
    Clin Infect Dis. 2020;71:471-472.
    PubMed    


  47. SHU CC, Tsai MK, Lin SW, Wang JY, et al
    Latent Tuberculosis Infection Increases in Kidney Transplantation Recipients Compared With Transplantation Candidates: A Neglected Perspective in Tuberculosis Control.
    Clin Infect Dis. 2020 Jul 4. pii: 5867272. doi: 10.1093.
    PubMed     Abstract available


    June 2020
  48. BISIMWA BC, Nachega JB, Warren RM, Theron G, et al
    Xpert MTB/RIF-detected Rifampicin Resistance is a Sub-Optimal Surrogate for Multidrug Resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications.
    Clin Infect Dis. 2020 Jun 26. pii: 5863452. doi: 10.1093.
    PubMed     Abstract available


  49. MARTINEZ L, Andrews JR
    Identifying priorities for testing and treatment of latent tuberculosis infection in the United States.
    Clin Infect Dis. 2020 Jun 26. pii: 5863155. doi: 10.1093.
    PubMed    


  50. NARDELL EA
    Time to revise our tuberculosis infection-latency-disease model in high-burden settings.
    Clin Infect Dis. 2020 Jun 25. pii: 5862697. doi: 10.1093.
    PubMed    


  51. JO Y, Shrestha S, Gomes I, Marks S, et al
    Model-Based Cost-Effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York and Texas.
    Clin Infect Dis. 2020 Jun 25. pii: 5862678. doi: 10.1093.
    PubMed     Abstract available


  52. JIANG Q, Liu Q, Ji L, Li J, et al
    Citywide Transmission of Multidrug-resistant Tuberculosis Under China's Rapid Urbanization: A Retrospective Population-based Genomic Spatial Epidemiological Study.
    Clin Infect Dis. 2020;71:142-151.
    PubMed     Abstract available


  53. LACOURSE SM, Richardson BA, Kinuthia J, Warr AJ, et al
    A randomized controlled trial of isoniazid to prevent Mycobacterium tuberculosis infection in Kenyan HIV-exposed uninfected infants.
    Clin Infect Dis. 2020 Jun 21. pii: 5860476. doi: 10.1093.
    PubMed     Abstract available


  54. PUYAT JH, Shulha HP, Balshaw R, Campbell JR, et al
    How well does TSTin3D predict risk of active tuberculosis in the Canadian immigrant population? An External Validation Study.
    Clin Infect Dis. 2020 Jun 18. pii: 5859579. doi: 10.1093.
    PubMed     Abstract available


  55. ECKOLD C, Kumar V, Weiner Rd J, Alisjahbana B, et al
    Impact of intermediate hyperglycaemia as well as diabetes on immune dysfunction in tuberculosis.
    Clin Infect Dis. 2020 Jun 13. pii: 5857148. doi: 10.1093.
    PubMed     Abstract available


  56. WILKINSON RJ
    Tuberculosis and type 2 Diabetes Mellitus: an inflammatory danger signal in the time of COVID-19.
    Clin Infect Dis. 2020 Jun 13. pii: 5857156. doi: 10.1093.
    PubMed    


  57. FOX GJ, Redwood L, Chang V, Ho J, et al
    The effectiveness of individual and environmental infection control measures in reducing the transmission of Mycobacterium tuberculosis: a systematic review.
    Clin Infect Dis. 2020 Jun 5. pii: 5853999. doi: 10.1093.
    PubMed     Abstract available


  58. KARAT AS, Gregg M, Barton HE, Calderon M, et al
    Evidence for the use of triage, respiratory isolation, and effective treatment to reduce the transmission of Mycobacterium tuberculosis in health care settings: a systematic review.
    Clin Infect Dis. 2020 Jun 5. pii: 5852552. doi: 10.1093.
    PubMed     Abstract available


  59. GRIFFITH DE, Cegielski JP
    Tuberculosis Healthcare Workers: There Goes My Hero.
    Clin Infect Dis. 2020 Jun 5. pii: 5853603. doi: 10.1093.
    PubMed    


    May 2020
  60. GAENSBAUER J
    Xpert Ultra assay on children's stool to diagnose pulmonary tuberculosis.
    Clin Infect Dis. 2020 May 25. pii: 5843708. doi: 10.1093.
    PubMed    


  61. CHIANG SS, Brooks MB, Jenkins HE, Rubenstein D, et al
    Concordance of drug resistance profiles between persons with drug-resistant tuberculosis and their household contacts: a systematic review and meta-analysis.
    Clin Infect Dis. 2020 May 25. pii: 5843623. doi: 10.1093.
    PubMed     Abstract available


  62. KABIR S, Rahman SMM, Ahmed S, Islam MS, et al
    Xpert Ultra assay on stool to diagnose pulmonary tuberculosis in children.
    Clin Infect Dis. 2020 May 18. pii: 5839814. doi: 10.1093.
    PubMed     Abstract available


  63. WALLES J, Tesfaye F, Jansson M, Balcha TT, et al
    Tuberculosis infection in women of reproductive age - a cross-sectional study at antenatal care clinics in an Ethiopian city.
    Clin Infect Dis. 2020 May 15. pii: 5837526. doi: 10.1093.
    PubMed     Abstract available


  64. SHIN SS, Modongo C, Zetola NM
    Twice-Daily vs. Once-Daily Dolutegravir in Patients With Human Immunodeficiency Virus-Tuberculosis Coinfection Receiving Rifampicin-Based Tuberculosis Therapy.
    Clin Infect Dis. 2020 May 14. pii: 5836979. doi: 10.1093.
    PubMed    


  65. DOOKIE N, Padayatchi N, Lessells RJ, Naicker CL, et al
    Individualised treatment of Multi-Drug Resistant Tuberculosis using Whole Genome Sequencing and Expanded Drug Susceptibility Testing.
    Clin Infect Dis. 2020 May 8. pii: 5834727. doi: 10.1093.
    PubMed     Abstract available


  66. PURYEAR SB, Fatch R, Beesiga B, Kekibiina A, et al
    Higher levels of alcohol use are associated with latent tuberculosis infection in adults living with HIV.
    Clin Infect Dis. 2020 May 6. pii: 5831355. doi: 10.1093.
    PubMed     Abstract available


  67. HORSBURGH CR
    "Plus Ca Change...".
    Clin Infect Dis. 2020;70:2119-2120.
    PubMed    


    April 2020
  68. MARURI F, Guo Y, Blackman A, van der Heijden YF, et al
    Resistance-conferring mutations on whole-genome sequencing of fluoroquinolone-resistant and -susceptible M. tuberculosis isolates: a proposed threshold for identifying resistance.
    Clin Infect Dis. 2020 Apr 29. pii: 5827013. doi: 10.1093.
    PubMed     Abstract available


  69. BOARDMAN NJ, Moore T, Freiman J, Tagliaferri G, et al
    Pulmonary tuberculosis disease among immigrant detainees: rapid disease detection, high prevalence of asymptomatic disease and implications for tuberculosis prevention.
    Clin Infect Dis. 2020 Apr 16. pii: 5820624. doi: 10.1093.
    PubMed     Abstract available


  70. BOUTON TC, Jacobson KR
    Symptom screens are not sufficient: the fight against tuberculosis needs better weapons.
    Clin Infect Dis. 2020 Apr 16. pii: 5820627. doi: 10.1093.
    PubMed    


  71. ALVAREZ GG, Zwerling AA, Duncan C, Pease C, et al
    Molecular epidemiology of Mycobacterium tuberculosis to describe the transmission dynamics among Inuit residing in Iqaluit Nunavut using whole genome sequencing.
    Clin Infect Dis. 2020 Apr 13. pii: 5819740. doi: 10.1093.
    PubMed     Abstract available


  72. ALFFENAAR JC, Gumbo T, Dooley KE, Peloquin CA, et al
    Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis.
    Clin Infect Dis. 2020;70:1774-1780.
    PubMed     Abstract available


  73. REUTER A, Furin J
    Treating drug-resistant tuberculosis infection: no more excuses.
    Clin Infect Dis. 2020 Apr 8. pii: 5817606. doi: 10.1093.
    PubMed    


    March 2020
  74. THOMAS BE, Kumar JV, Chiranjeevi M, Shah D, et al
    Evaluation of the accuracy of 99DOTS, a novel cellphone-based strategy for monitoring adherence to tuberculosis medications: Comparison of digital adherence data with urine isoniazid testing.
    Clin Infect Dis. 2020 Mar 28. pii: 5812993. doi: 10.1093.
    PubMed     Abstract available


  75. SCHMIT KM, Wortham JM, Ho CS, Powell KM, et al
    Analysis of severe adverse events reported among patients receiving isoniazid-rifapentine treatment for latent Mycobacterium tuberculosis infection - United States, 2012-2016.
    Clin Infect Dis. 2020 Mar 18. pii: 5809293. doi: 10.1093.
    PubMed     Abstract available


  76. SRINIVASAN V, Ha VTN, Vinh DN, Thai PVK, et al
    Sources of multi-drug resistance in patients with previous isoniazid resistant tuberculosis identified using whole genome sequencing: A longitudinal cohort study.
    Clin Infect Dis. 2020 Mar 13. pii: 5804256. doi: 10.1093.
    PubMed     Abstract available


  77. LOVEDAY M, Hughes J, Sunkari B, Master I, et al
    Maternal and infant outcomes among pregnant women treated for multidrug/rifampicin-resistant tuberculosis in South Africa.
    Clin Infect Dis. 2020 Mar 6. pii: 5788430. doi: 10.1093.
    PubMed     Abstract available


  78. CHENG MP, Marty FM
    Reply to Aronson et al.
    Clin Infect Dis. 2020;70:1262.
    PubMed    


    February 2020
  79. WOODMAN M, Grandjean L
    Detecting Tuberculosis in Prisons: Switching Off the Disease at its Source.
    Clin Infect Dis. 2020 Feb 17. pii: 5736587. doi: 10.1093.
    PubMed    


  80. SANTOS ADS, Oliveira RD, Lemos EF, Lima F, et al
    Yield, Efficiency and Costs of Mass Screening Algorithms for Tuberculosis in Brazilian Prisons.
    Clin Infect Dis. 2020 Feb 17. pii: 5736588. doi: 10.1093.
    PubMed     Abstract available


  81. REICHLER MR, Khan A, Yuan Y, Chen B, et al
    Duration of Exposure Among Close Contacts of Patients With Infectious Tuberculosis and Risk of Latent Tuberculosis Infection.
    Clin Infect Dis. 2020 Feb 11. pii: 5733747. doi: 10.1093/cid/ciz1044.
    PubMed     Abstract available


  82. VAN DER WERF MJ, Rosales-Klintz S, de Vlas SJ
    Screening for Latent Tuberculosis (TB) Infection in Low TB Incidence Countries.
    Clin Infect Dis. 2020;70:716-717.
    PubMed    


  83. MIYAHARA S, Ramchandani R, Kim S, Evans SR, et al
    Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials.
    Clin Infect Dis. 2020;70:698-703.
    PubMed     Abstract available


    January 2020
  84. KORNFELD H, Sahukar SB, Procter-Gray E, Kumar NP, et al
    Impact of Diabetes and Low Body Mass Index on Tuberculosis Treatment Outcomes.
    Clin Infect Dis. 2020 Jan 19. pii: 5709634. doi: 10.1093.
    PubMed     Abstract available


  85. UGARTE-GIL C, Pearson F, Moore D, Critchley J, et al
    Reply to Yates and Barr.
    Clin Infect Dis. 2020;70:545-546.
    PubMed    


  86. HONG H, Dowdy DW
    Reply to Chen, Song, and Liu.
    Clin Infect Dis. 2020;70:547-548.
    PubMed    


  87. CHEN HL, Song YP, Liu K
    Prediction Model Needs More Improvements Before Clinical Application.
    Clin Infect Dis. 2020;70:546-547.
    PubMed    


  88. PARK JH, Choi EJ, Park HS, Choi SH, et al
    Treatment of latent tuberculosis infection based on the interferon-gamma releasing assay in allogeneic stem cell transplant recipients.
    Clin Infect Dis. 2020 Jan 13. pii: 5701499. doi: 10.1093.
    PubMed     Abstract available


  89. SOSSEN B, Broger T, Kerkhoff AD, Schutz C, et al
    'SILVAMP TB LAM' rapid urine tuberculosis test predicts mortality in hospitalized HIV patients in South Africa.
    Clin Infect Dis. 2020 Jan 9. pii: 5699650. doi: 10.1093.
    PubMed     Abstract available


  90. LI R, Nordio F, Huang CC, Contreras C, et al
    Two clinical prediction tools to improve tuberculosis contact investigation.
    Clin Infect Dis. 2020 Jan 6. pii: 5697300. doi: 10.1093/cid/ciz1221.
    PubMed     Abstract available


  91. RENS NE, Uyl-de Groot CA, Goldhaber-Fiebert JD, Croda J, et al
    Cost-Effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis.
    Clin Infect Dis. 2020 Jan 6. pii: 5697286. doi: 10.1093/cid/ciz1212.
    PubMed     Abstract available


    December 2019
  92. BOGLIONE L, Lipani F, Lucchini AM, Salvador E, et al
    Antiviral therapy in patients with HBV treated for tuberculosis: a forgotten issue.
    Clin Infect Dis. 2019 Dec 17. pii: 5679635. doi: 10.1093/cid/ciz1199.
    PubMed    


  93. KENDALL EA, Malhotra S, Cook-Scalise S, Dowdy DW, et al
    Clinical impact of rapid drug susceptibility testing to accompany fluoroquinolone-containing universal tuberculosis regimens: a Markov model.
    Clin Infect Dis. 2019 Dec 9. pii: 5669959. doi: 10.1093/cid/ciz1179.
    PubMed     Abstract available


  94. NOGUERA-JULIAN A, Calzada-HernAndez J, Brinkmann F, Basu Roy R, et al
    Tuberculosis disease in children and adolescents on therapy with anti-tumor necrosis factor-alpha agents: a collaborative, multi-centre ptbnet study.
    Clin Infect Dis. 2019 Dec 4. pii: 5651260. doi: 10.1093/cid/ciz1138.
    PubMed     Abstract available


  95. NOLT D
    Granulomas and guidelines - the search for tuberculosis during TNF-alpha inhibition.
    Clin Infect Dis. 2019 Dec 4. pii: 5651255. doi: 10.1093/cid/ciz1139.
    PubMed    


    November 2019
  96. GUPTA-WRIGHT A, Fielding K, Wilson D, van Oosterhout JJ, et al
    Tuberculosis in hospitalised patients with HIV: clinical characteristics, mortality, and implications from the STAMP trial.
    Clin Infect Dis. 2019 Nov 29. pii: 5645290. doi: 10.1093/cid/ciz1133.
    PubMed     Abstract available


  97. WALSH KF, Koenig SP
    Missed Opportunities with Fatal Consequences: The Need for Earlier Initiation of Intensified Care for Patients at Highest Risk of Mortality from HIV-Associated Tuberculosis.
    Clin Infect Dis. 2019 Nov 29. pii: 5645295. doi: 10.1093/cid/ciz1134.
    PubMed    


  98. FLYNN AG, Aiona K, Haas MK, Reves R, et al
    Clinical Characteristics of Active Tuberculosis Diagnosed after Starting Treatment for Latent Tuberculosis Infection.
    Clin Infect Dis. 2019 Nov 27. pii: 5644105. doi: 10.1093/cid/ciz1157.
    PubMed     Abstract available


  99. RAVIMOHAN S, Maenetje P, Auld SC, Ncube I, et al
    A Common NLRC4 Gene Variant Associates With Inflammation and Pulmonary Function in Human Immunodeficiency Virus and Tuberculosis.
    Clin Infect Dis. 2019 Nov 22. pii: 5637499. doi: 10.1093.
    PubMed     Abstract available


  100. KEMPKER RR, Mikiashvili L, Zhao Y, Benkeser D, et al
    Clinical Outcomes among Patients with Drug-resistant Tuberculosis receiving Bedaquiline or Delamanid Containing Regimens.
    Clin Infect Dis. 2019 Nov 12. pii: 5622604. doi: 10.1093/cid/ciz1107.
    PubMed     Abstract available


  101. SEUNG KJ, Khan P, Franke MF, Ahmed S, et al
    Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.
    Clin Infect Dis. 2019 Nov 2. pii: 5611120. doi: 10.1093/cid/ciz1084.
    PubMed     Abstract available


    October 2019
  102. SVENSSON EM, Dian S, Te Brake L, Ganiem AR, et al
    Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculosis meningitis trials.
    Clin Infect Dis. 2019 Oct 30. pii: 5609415. doi: 10.1093/cid/ciz1071.
    PubMed     Abstract available


  103. SILVEIRA-MATTOS PS, Barreto-Duarte B, Vasconcelos B, Fukutani KF, et al
    Differential expression of activation markers by Mycobacterium tuberculosis-specific CD4+ T-cell distinguishes extrapulmonary from pulmonary tuberculosis and latent infection.
    Clin Infect Dis. 2019 Oct 30. pii: 5609412. doi: 10.1093/cid/ciz1070.
    PubMed     Abstract available


  104. KOENIG SP, Kim A, Shepherd BE, Cesar C, et al
    Increased Mortality after Tuberculosis Treatment Completion in Persons with HIV in Latin America.
    Clin Infect Dis. 2019 Oct 20. pii: 5601170. doi: 10.1093/cid/ciz1032.
    PubMed     Abstract available


  105. NAIDOO K, Hassan-Moosa R, Mlotshwa P, Yende-Zuma N, et al
    High Rates of Drug-induced Liver Injury in People Living With HIV Coinfected With Tuberculosis (TB) Irrespective of Antiretroviral Therapy Timing During Antituberculosis Treatment: Results From the Starting Antiretroviral Therapy at Three Points in TB
    Clin Infect Dis. 2019 Oct 17. pii: 5589114. doi: 10.1093.
    PubMed     Abstract available


  106. SINGH N
    Unique Rarity of Tuberculosis and Granulomatous Opportunistic Infections in Hematopoietic Cell Transplant Recipients.
    Clin Infect Dis. 2019 Oct 4. pii: 5581232. doi: 10.1093.
    PubMed    


    September 2019
  107. SHAH M, Paradis S, Betz J, Beylis N, et al
    Multicenter Study of the Accuracy of the BD MAX MDR-TB Assay for Detection of Mycobacterium tuberculosis Complex and Mutations Associated with Resistance to Rifampin and Isoniazid.
    Clin Infect Dis. 2019 Sep 27. pii: 5574845. doi: 10.1093.
    PubMed     Abstract available


  108. KUBJANE M, Berkowitz N, Goliath R, Levitt NS, et al
    Tuberculosis, HIV and the association with transient hyperglycaemia in peri-urban South Africa.
    Clin Infect Dis. 2019 Sep 26. pii: 5574636. doi: 10.1093.
    PubMed     Abstract available


  109. MASE S, Chorba T, Parks S, Belanger A, et al
    Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis in the United States.
    Clin Infect Dis. 2019 Sep 26. pii: 5574390. doi: 10.1093.
    PubMed     Abstract available


  110. SWIFT MD, Molella RG, Vaughn AIS, Breeher LE, et al
    Determinants of Latent Tuberculosis Treatment Acceptance and Completion in Healthcare Personnel.
    Clin Infect Dis. 2019 Sep 25. pii: 5573404. doi: 10.1093.
    PubMed     Abstract available


  111. AULD SC, Maenetje P, Ravimohan S, Weissman D, et al
    Declines in Lung Function After Antiretroviral Therapy Initiation in Adults With Human Immunodeficiency Virus and Tuberculosis: A Potential Manifestation of Respiratory Immune Reconstitution Inflammatory Syndrome.
    Clin Infect Dis. 2019 Sep 25. pii: 5573460. doi: 10.1093.
    PubMed     Abstract available


  112. DU Y, Qiu C, Chen X, Wang J, et al
    Treatment outcome of a shorter regimen containing clofazimine for multidrug-resistant tuberculosis: a randomized control trial in China.
    Clin Infect Dis. 2019 Sep 24. pii: 5573036. doi: 10.1093.
    PubMed     Abstract available


  113. WOLF A, Padayatchi N, Naidoo K, Master I, et al
    Spatial Temporal Clustering of Multi- and Extensively Drug Resistant Tuberculosis is Associated with HIV Status and Drug-susceptibility Pattern in KwaZulu-Natal, South Africa.
    Clin Infect Dis. 2019 Sep 20. pii: 5572101. doi: 10.1093.
    PubMed     Abstract available


  114. KENYON C, Peeters D, Goedgezelschap A, Vlieghe E, et al
    A Color-conscious Diagnosis.
    Clin Infect Dis. 2019;69:1259-1261.
    PubMed    


    August 2019
  115. ZELNER J
    Is a more data-driven approach the future of Tuberculosis transmission modeling?
    Clin Infect Dis. 2019 Aug 17. pii: 5550891. doi: 10.1093.
    PubMed    


  116. WEINER J, Domaszewska T, Donkor S, Kaufmann SHE, et al
    Changes in transcript, metabolite and antibody reactivity during the early protective immune response in humans to Mycobacterium tuberculosis infection.
    Clin Infect Dis. 2019 Aug 15. pii: 5550193. doi: 10.1093.
    PubMed     Abstract available


    July 2019
  117. NELSON KN, Jenness SM, Mathema B, Lopman BA, et al
    Social mixing and clinical features linked with transmission in a network of extensively drug-resistant (XDR) tuberculosis cases in KwaZulu-Natal, South Africa.
    Clin Infect Dis. 2019 Jul 12. pii: 5531655. doi: 10.1093.
    PubMed     Abstract available


  118. ARONSON JR, Rezvani AR, Subramanian A
    Incidence of Active Tuberculosis Following Hematopoietic Cell Transplantation: A Small but Real Threat.
    Clin Infect Dis. 2019 Jul 11. pii: 5531496. doi: 10.1093.
    PubMed    


    June 2019
  119. XIN H, Zhang H, Yang S, Liu J, et al
    5-year follow-up of active tuberculosis development from latent infection in rural China.
    Clin Infect Dis. 2019 Jun 28. pii: 5525170. doi: 10.1093.
    PubMed     Abstract available


  120. DALE KD, Trauer JM, Dodd PJ, Houben RMGJ, et al
    Estimating long-term tuberculosis reactivation rates in Australian migrants.
    Clin Infect Dis. 2019 Jun 27. pii: 5524225. doi: 10.1093.
    PubMed     Abstract available


  121. RAVIMOHAN S, Auld SC, Maenetje P, Ratsela N, et al
    Lung injury on antiretroviral therapy in adults with HIV/TB.
    Clin Infect Dis. 2019 Jun 26. pii: 5523721. doi: 10.1093.
    PubMed     Abstract available


  122. SHARLING L, Marks SM, Goodman M, Chorba T, et al
    Rifampin-Resistant Tuberculosis In The United States, 1998-2014.
    Clin Infect Dis. 2019 Jun 22. pii: 5522413. doi: 10.1093.
    PubMed     Abstract available


  123. VERMA R, Swift BMC, Handley-Hartill W, Lee JK, et al
    A novel high sensitivity bacteriophage-based assay identifies low level M. tuberculosis bacteraemia in immunocompetent patients with active and incipient TB.
    Clin Infect Dis. 2019 Jun 22. pii: 5522421. doi: 10.1093.
    PubMed     Abstract available


  124. MALIK AA, Fuad J, Siddiqui S, Amanullah F, et al
    TB Preventive Therapy for individuals exposed to drug-resistant tuberculosis: feasibility and safety of a community-based delivery of fluoroquinolone-containing preventive regimen.
    Clin Infect Dis. 2019 Jun 12. pii: 5514486. doi: 10.1093.
    PubMed     Abstract available


  125. WALKER NF, Opondo C, Meintjes G, Jhilmeet N, et al
    Invariant Natural Killer T cell dynamics in HIV-associated tuberculosis.
    Clin Infect Dis. 2019 Jun 12. pii: 5514487. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  126. REICHLER MR, Khan A, Sterling TR, Zhao H, et al
    Risk Factors for Tuberculosis and Effect of Preventive Therapy Among Close Contacts of Persons with Infectious Tuberculosis.
    Clin Infect Dis. 2019 May 24. pii: 5498700. doi: 10.1093.
    PubMed     Abstract available


  127. SALAZAR-AUSTIN N, Cohn S, Barnes GL, Tladi M, et al
    Improving TPT Uptake: A Cluster-Randomized Trial of Symptom-Based Versus Tuberculin Skin Test-Based Screening of Household Tuberculosis Contacts Less than 5 Years of Age.
    Clin Infect Dis. 2019 May 24. pii: 5498606. doi: 10.1093.
    PubMed     Abstract available


  128. YATES TA, Barr DA
    Tuberculosis and dysglycaemia.
    Clin Infect Dis. 2019 May 24. pii: 5498398. doi: 10.1093.
    PubMed    


  129. RAMACHANDRAN G, Chandrasekaran P, Gaikwad S, Hemanth Kumar AK, et al
    Sub-therapeutic rifampicin concentration is associated with unfavourable tuberculosis treatment outcomes.
    Clin Infect Dis. 2019 May 10. pii: 5487939. doi: 10.1093.
    PubMed     Abstract available


    April 2019
  130. GARDNER TOREN K, Spitters C, Pecha M, Bhattarai S, et al
    Tuberculosis in Older Adults: Seattle & King County, Washington.
    Clin Infect Dis. 2019 Apr 12. pii: 5448903. doi: 10.1093.
    PubMed     Abstract available


  131. HONG H, Dowdy DW, Dooley KE, Francis HW, et al
    Aminoglycoside-Induced Hearing Loss Among Patients Being Treated for Drug-Resistant Tuberculosis in South Africa: A Prediction Model.
    Clin Infect Dis. 2019 Apr 9. pii: 5432319. doi: 10.1093.
    PubMed     Abstract available


  132. UGARTE-GIL C, Alisjahbana B, Ronacher K, Riza AL, et al
    Diabetes mellitus among pulmonary tuberculosis patients from four TB-endemic countries: the TANDEM study.
    Clin Infect Dis. 2019 Apr 8. pii: 5431210. doi: 10.1093.
    PubMed     Abstract available


  133. TSANG CA, Shah N, Armstrong LR, Marks SM, et al
    Eligibility for a Shorter Treatment Regimen for Multidrug-resistant Tuberculosis in the United States, 2011-2016.
    Clin Infect Dis. 2019 Apr 4. pii: 5427063. doi: 10.1093.
    PubMed     Abstract available


  134. THAO LTP, Wolbers M, Heemskerk AD, Thi Hoang Mai N, et al
    Dynamic prediction of death in patients with tuberculous meningitis using time-updated Glasgow coma score and plasma sodium measurements.
    Clin Infect Dis. 2019 Apr 4. pii: 5427068. doi: 10.1093.
    PubMed     Abstract available


    March 2019
  135. SURYAVANSHI N, Murrill M, Gupta A, Hughes M, et al
    Willingness to Take Multidrug-Resistant Tuberculosis (MDR-TB) Preventive Therapy among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multi-Site Cross-Sectional Study.
    Clin Infect Dis. 2019 Mar 28. pii: 5421246. doi: 10.1093.
    PubMed     Abstract available


  136. ROE J, Venturini C, Gupta RK, Gurry C, et al
    Blood transcriptomic stratification of short-term risk in contacts of tuberculosis.
    Clin Infect Dis. 2019 Mar 28. pii: 5421263. doi: 10.1093.
    PubMed     Abstract available


  137. DOOLEY KE, Kaplan R, Mwelase N, Grinsztejn B, et al
    Dolutegravir-Based Antiretroviral Therapy for Patients Co-Infected with Tuberculosis and Hiv: A Multicenter, Noncomparative, Open-Label, Randomized Trial.
    Clin Infect Dis. 2019 Mar 28. pii: 5421214. doi: 10.1093.
    PubMed     Abstract available


  138. GUPTA A, Swindells S, Kim S, Hughes MD, et al
    Feasibility of Identifying Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease.
    Clin Infect Dis. 2019 Mar 28. pii: 5426963. doi: 10.1093.
    PubMed     Abstract available


  139. MAARTENS G, Meintjes G
    Managing HIV-associated tuberculosis in the dolutegravir era.
    Clin Infect Dis. 2019 Mar 25. pii: 5419061. doi: 10.1093.
    PubMed    


  140. LUI GCY, Wong NS, Wong RYK, Tse YK, et al
    Antiviral therapy for hepatitis B prevents liver injury in patients with tuberculosis and hepatitis B co-infection.
    Clin Infect Dis. 2019 Mar 22. pii: 5421304. doi: 10.1093.
    PubMed     Abstract available


  141. TORNHEIM JA, Starks AM, Rodwell TC, Gardy JL, et al
    Building the framework for standardized clinical laboratory reporting of next generation sequencing data for resistance-associated mutations in Mycobacterium tuberculosis complex.
    Clin Infect Dis. 2019 Mar 18. pii: 5382557. doi: 10.1093.
    PubMed     Abstract available


  142. RONALD LA, Campbell JR, Rose C, Balshaw R, et al
    Estimated impact of World Health Organization latent tuberculosis screening guidelines in a low TB incidence region: retrospective cohort study.
    Clin Infect Dis. 2019 Mar 11. pii: 5374592. doi: 10.1093.
    PubMed     Abstract available


  143. KATRAK S, Barry P
    Preventing tuberculosis disease - making a case for enhanced TB screening in people immigrating to low-incidence countries.
    Clin Infect Dis. 2019 Mar 11. pii: 5373169. doi: 10.1093.
    PubMed    


  144. ALFFENAAR JC, Heysell SK, Mpagama SG
    Therapeutic Drug Monitoring: The Need for Practical Guidance.
    Clin Infect Dis. 2019;68:1065-1066.
    PubMed    


    February 2019
  145. PERUMAL R, Padayatchi N, Yende-Zuma N, Naidoo A, et al
    A moxifloxacin-based regimen for the treatment of recurrent drug-sensitive pulmonary tuberculosis: An open-label randomised controlled trial.
    Clin Infect Dis. 2019 Feb 27. pii: 5365529. doi: 10.1093.
    PubMed     Abstract available


  146. BULABULA ANH, Nelson JA, Musafiri EM, Machekano R, et al
    Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Clin Infect Dis. 2019 Feb 13. pii: 5316466. doi: 10.1093/cid/ciy1105.
    PubMed     Abstract available


  147. POLSFUSS S, Hofmann-Thiel S, Merker M, Krieger D, et al
    Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Clin Infect Dis. 2019 Feb 2. pii: 5305974. doi: 10.1093.
    PubMed     Abstract available


    January 2019
  148. WALSH KF, Vilbrun SC, Souroutzidis A, Delva S, et al
    Improved Outcomes with High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment in Haiti.
    Clin Infect Dis. 2019 Jan 29. pii: 5304006. doi: 10.1093.
    PubMed     Abstract available


  149. BORAND L, de Lauzanne A, Nguyen NL, Cheng S, et al
    Isolation of Nontuberculous Mycobacteria in Southeast Asian and African Human Immunodeficiency Virus-infected Children With Suspected Tuberculosis.
    Clin Infect Dis. 2019 Jan 28. pii: 5303788. doi: 10.1093.
    PubMed     Abstract available


  150. CHENG MP, Kusztos AE, Bold TD, Ho VT, et al
    Risk of Latent Tuberculosis Reactivation after Hematopoietic-Cell Transplantation.
    Clin Infect Dis. 2019 Jan 28. pii: 5303791. doi: 10.1093.
    PubMed     Abstract available


    November 2018
  151. BOLHUIS MS, Akkerman OW, Sturkenboom MGG, Ghimire S, et al
    Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  152. STURKENBOOM MGG, Simbar N, Akkerman OW, Ghimire S, et al
    Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  153. SRIVASTAVA S, Deshpande D, Magombedze G, Gumbo T, et al
    Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  154. MAGOMBEDZE G, Pasipanodya JG, Srivastava S, Deshpande D, et al
    Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  155. SRIVASTAVA S, Deshpande D, Nuermberger E, Lee PS, et al
    The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  156. FALZON D, Jaramillo E, Gilpin C, Weyer K, et al
    The Role of Novel Approaches and New Findings in the Pharmacology of Tuberculosis Medicines in Improving Treatment Outcomes.
    Clin Infect Dis. 2018;67.
    PubMed    


  157. DESHPANDE D, Pasipanodya JG, Mpagama SG, Bendet P, et al
    Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  158. DESHPANDE D, Alffenaar JC, Koser CU, Dheda K, et al
    d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  159. DESHPANDE D, Pasipanodya JG, Srivastava S, Bendet P, et al
    Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  160. PASIPANODYA JG, Smythe W, Merle CS, Olliaro PL, et al
    Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  161. DESHPANDE D, Pasipanodya JG, Mpagama SG, Srivastava S, et al
    Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  162. DESHPANDE D, Srivastava S, Nuermberger E, Koeuth T, et al
    Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  163. GUMBO T, Alffenaar JC
    Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs.
    Clin Infect Dis. 2018;67.
    PubMed     Abstract available


  164. GANMAA D, Khudyakov P, Buyanjargal U, Jargalsaikhan B, et al
    Prevalence and determinants of QuantiFERON-diagnosed tuberculosis infection in 9,810 Mongolian schoolchildren.
    Clin Infect Dis. 2018 Nov 27. pii: 5210883. doi: 10.1093.
    PubMed     Abstract available


  165. CUBILLOS-ANGULO JM, Arriaga MB, Silva EC, Muller BLA, et al
    Polymorphisms in TLR4 and TNFA and Risk of Mycobacterium tuberculosis Infection and Development of Active Disease in Contacts of Tuberculosis Cases in Brazil: A Prospective Cohort Study.
    Clin Infect Dis. 2018 Nov 24. pii: 5204461. doi: 10.1093/cid/ciy1001.
    PubMed     Abstract available


  166. DORJEE K, Topgyal S, Dorjee C, Tsundue T, et al
    High Prevalence of Active and Latent Tuberculosis in Children and Adolescents in Tibetan Schools in India: The Zero TB Kids Initiative in Tibetan Refugee Children.
    Clin Infect Dis. 2018 Nov 20. pii: 5193441. doi: 10.1093.
    PubMed     Abstract available


  167. RAJAN JV, Semitala FC, Mehta T, Seielstad M, et al
    A Novel, 5-Transcript, Whole-blood Gene-expression Signature for Tuberculosis Screening Among People Living With Human Immunodeficiency Virus.
    Clin Infect Dis. 2018 Nov 20. pii: 5193271. doi: 10.1093.
    PubMed     Abstract available


  168. MIGLIORI GB
    Evolution of programmatic definitions used in tuberculosis prevention and care.
    Clin Infect Dis. 2018 Nov 20. pii: 5193464. doi: 10.1093.
    PubMed    


  169. TING DSW, Tan TE, Lim CCT
    Development and Validation of a Deep Learning System for Detection of Active Pulmonary Tuberculosis on Chest Radiographs: Clinical and Technical Considerations.
    Clin Infect Dis. 2018 Nov 12. pii: 5173988. doi: 10.1093.
    PubMed    


  170. HWANG EJ, Park S, Jin KN, Kim JI, et al
    Development and Validation of a Deep Learning-Based Automatic Detection Algorithm for Active Pulmonary Tuberculosis on Chest Radiographs.
    Clin Infect Dis. 2018 Nov 12. pii: 5174137. doi: 10.1093.
    PubMed     Abstract available


  171. LOWENTHAL P, Lin SG, Desmond E, Shah N, et al
    Evaluation of the impact of a sequencing assay for detection of drug resistance on the clinical management of tuberculosis.
    Clin Infect Dis. 2018 Nov 1. pii: 5154873. doi: 10.1093.
    PubMed     Abstract available


  172. TRAUER JM, Dodd PJ, Gomes MGM, Gomez GB, et al
    The Importance of Heterogeneity to the Epidemiology of Tuberculosis.
    Clin Infect Dis. 2018 Nov 1. pii: 5154892. doi: 10.1093.
    PubMed     Abstract available


    October 2018
  173. HUANG H, Ding N, Yang T, Li C, et al
    Cross-sectional whole-genome sequencing and epidemiological study of multidrug-resistant Mycobacterium tuberculosis in China.
    Clin Infect Dis. 2018 Oct 15. pii: 5130581. doi: 10.1093.
    PubMed     Abstract available


    September 2018
  174. LESOSKY M, Rangaka MX, Pienaar C, Coussens AK, et al
    Plasma biomarkers to detect prevalent, or predict progressive, HIV-1-associated tuberculosis.
    Clin Infect Dis. 2018 Sep 26. pii: 5106993. doi: 10.1093.
    PubMed     Abstract available


  175. VAN KAMPEN SC, Jones R, Kisembo H, Houben RMGJ, et al
    Chronic respiratory symptoms and lung abnormalities among people with a history of tuberculosis in Uganda: a national survey.
    Clin Infect Dis. 2018 Sep 18. pii: 5099459. doi: 10.1093.
    PubMed     Abstract available


  176. FOX GJ, Nguyen VN, Dinh NS, Nghiem LPH, et al
    Post-treatment Mortality Among Patients With Tuberculosis: A Prospective Cohort Study of 10 964 Patients in Vietnam.
    Clin Infect Dis. 2018 Sep 7. pii: 5092716. doi: 10.1093.
    PubMed     Abstract available


  177. BUI DP, Oren E, Roe DJ, Brown HE, et al
    A Case Control Study to Identify Community Venues Associated with Genetically Clustered Multidrug-Resistant Tuberculosis Disease in Lima, Peru.
    Clin Infect Dis. 2018 Sep 5. pii: 5090843. doi: 10.1093.
    PubMed     Abstract available


    August 2018
  178. STEIN CM, Nsereko M, Malone LL, Okware B, et al
    Long-term stability of resistance to latent M. tuberculosis infection in highly exposed TB household contacts in Kampala, Uganda.
    Clin Infect Dis. 2018 Aug 28. pii: 5085255. doi: 10.1093.
    PubMed     Abstract available


  179. ZHAO Y, Fox T, Manning K, Stewart A, et al
    Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug resistant tuberculosis: a retrospective cohort study.
    Clin Infect Dis. 2018 Aug 24. pii: 5079132. doi: 10.1093.
    PubMed     Abstract available


  180. ROBERTSON K, Oladeji B, Jiang H, Kumwenda J, et al
    HIV-1 and TB Co-infection in Multinational Resource Limited Settings: Increased neurological dysfunction.
    Clin Infect Dis. 2018 Aug 20. pii: 5076927. doi: 10.1093.
    PubMed     Abstract available


    July 2018
  181. NGWIRA LG, Corbett EL, Khundi M, Barnes GL, et al
    Screening for tuberculosis with Xpert MTB/RIF versus fluorescent microscopy among adults newly diagnosed with HIV in rural Malawi: a cluster randomized trial (CHEPETSA).
    Clin Infect Dis. 2018 Jul 27. pii: 5060257. doi: 10.1093.
    PubMed     Abstract available


  182. HOUBEN RMGJ, Lalli M, Kranzer K, Menzies NA, et al
    What if they don't have tuberculosis? The consequences and trade-offs involved in false-positive diagnoses of tuberculosis.
    Clin Infect Dis. 2018 Jul 5. pii: 5049169. doi: 10.1093.
    PubMed     Abstract available


    June 2018
  183. SVENSSON EM, Svensson RJ, Te Brake LHM, Boeree MJ, et al
    The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.
    Clin Infect Dis. 2018;67:34-41.
    PubMed     Abstract available


  184. MOORE CC, Jacob ST, Banura P, Zhang J, et al
    Etiology of Sepsis in Uganda using a Quantitative PCR-based TaqMan Array Card.
    Clin Infect Dis. 2018 Jun 4. pii: 5032704. doi: 10.1093.
    PubMed     Abstract available


    May 2018
  185. DIAN S, Rahmadi R, Laarhoven AV, Ganiem AR, et al
    Predicting mortality of tuberculous meningitis.
    Clin Infect Dis. 2018 May 31. pii: 5025876. doi: 10.1093.
    PubMed    


  186. GARCIA-PRATS AJ, Draper HR, Finlayson H, Winckler J, et al
    Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis.
    Clin Infect Dis. 2018 May 16. pii: 4996923. doi: 10.1093.
    PubMed     Abstract available


    April 2018
  187. XIE YL, Cronin WA, Proschan M, Oatis R, et al
    Transmission of Mycobacterium tuberculosis from patients who are nucleic acid amplification test- negative.
    Clin Infect Dis. 2018 Apr 24. pii: 4984625. doi: 10.1093.
    PubMed     Abstract available


  188. ZUUR MA, Pasipanodya JG, van Soolingen D, van der Werf TS, et al
    Intermediate Susceptibility Dose-Dependent Breakpoints For High Dose Rifampicin, Isoniazid and Pyrazinamide Treatment in multidrug-resistant tuberculosis Programmes.
    Clin Infect Dis. 2018 Apr 24. pii: 4984540. doi: 10.1093.
    PubMed     Abstract available


  189. VON REYN CF, Horsburgh CR
    Non-tuberculous mycobacteria and testing for LTBI.
    Clin Infect Dis. 2018 Apr 18. pii: 4975392. doi: 10.1093.
    PubMed    


    March 2018
  190. JOHNSON KT, Churchyard GJ, Sohn H, Dowdy DW, et al
    Cost-effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings.
    Clin Infect Dis. 2018 Mar 30. pii: 4956926. doi: 10.1093.
    PubMed     Abstract available


  191. VAN LAARHOVEN A, Koeken VACM, Dian S, Ganiem AR, et al
    Neuromarker Levels Also Predict Mortality in Adult Tuberculous Meningitis.
    Clin Infect Dis. 2018 Mar 30. pii: 4956701. doi: 10.1093.
    PubMed    


  192. FRIGATI L, Archary M, Rabie H, Penazzato M, et al
    Priorities for Decreasing Morbidity and Mortality in Children With Advanced HIV Disease.
    Clin Infect Dis. 2018;66.
    PubMed     Abstract available


  193. FORD N, Meintjes G, Calmy A, Bygrave H, et al
    Managing Advanced HIV Disease in a Public Health Approach.
    Clin Infect Dis. 2018;66.
    PubMed     Abstract available


  194. PASIPANODYA JG, Gumbo T
    Individualizing Tuberculosis Treatment: Are Tuberculosis Programs In High Burden Settings Ready For Prime Time Therapeutic Drug Monitoring?
    Clin Infect Dis. 2018 Mar 3. pii: 4919551. doi: 10.1093.
    PubMed    


  195. SEKAGGYA-WILTSHIRE C, von Braun A, Lamorde M, Ledergerber B, et al
    Delayed Sputum Conversion in TB-HIV Co-Infected Patients with Low Isoniazid and Rifampicin Concentrations.
    Clin Infect Dis. 2018 Mar 3. pii: 4919550. doi: 10.1093.
    PubMed     Abstract available


    February 2018
  196. BROOKS KM, George JM, Pau AK, Rupert A, et al
    Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir with Once-Weekly Isoniazid and Rifapentine.
    Clin Infect Dis. 2018 Feb 3. pii: 4836314. doi: 10.1093.
    PubMed     Abstract available


    January 2018
  197. YU MC, Chiang CY, Lee JJ, Chien ST, et al
    Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up.
    Clin Infect Dis. 2018 Jan 31. pii: 4831095. doi: 10.1093.
    PubMed     Abstract available


  198. MARAIS S, Roos I, Mitha A, Mabusha SJ, et al
    Spinal tuberculosis: Clinicoradiological findings in 274 patients.
    Clin Infect Dis. 2018 Jan 11. pii: 4797620. doi: 10.1093.
    PubMed     Abstract available


  199. DEGNER NR, Wang JY, Golub JE, Karakousis PC, et al
    Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment.
    Clin Infect Dis. 2018;66:198-205.
    PubMed     Abstract available


  200. LACOURSE SM, Cranmer LM, Njuguna IN, Gatimu J, et al
    Urine TB lipoarabinomannan (LAM) predicts mortality in hospitalized HIV-infected children.
    Clin Infect Dis. 2018 Jan 6. pii: 4792803. doi: 10.1093.
    PubMed     Abstract available


    December 2017
  201. BRUST JCM, Shah NS, Mlisana K, Moodley P, et al
    Improved survival and cure rates with concurrent treatment for MDR-TB/HIV co-infection in South Africa.
    Clin Infect Dis. 2017 Dec 26. pii: 4774985. doi: 10.1093/cid/cix1125.
    PubMed     Abstract available


    November 2017
  202. KOSER CU, Koeser LA, Dolinger DL
    Limited evidence for need for region-specific, genotypic drug-susceptibility assays for Mycobacterium tuberculosis.
    Clin Infect Dis. 2017 Nov 22. pii: 4647356. doi: 10.1093/cid/cix1042.
    PubMed    


  203. GRIESEL R, Stewart A, van der Plas H, Sikhondze W, et al
    Optimizing Tuberculosis Diagnosis in HIV-Infected Inpatients Meeting the Criteria of Seriously Ill in the WHO Algorithm.
    Clin Infect Dis. 2017 Nov 6. doi: 10.1093.
    PubMed     Abstract available


    October 2017
  204. HUAMAN MA, Ticona E, Miranda G, Kryscio RJ, et al
    The Relationship between Latent Tuberculosis Infection and Acute Myocardial Infarction.
    Clin Infect Dis. 2017 Oct 21. doi: 10.1093.
    PubMed     Abstract available


  205. GUTHRIE JL, Kong C, Roth D, Jorgensen D, et al
    Molecular Epidemiology of Tuberculosis in British Columbia, Canada - A 10-Year Retrospective Study.
    Clin Infect Dis. 2017 Oct 21. doi: 10.1093.
    PubMed     Abstract available


  206. MARTINEZ L, Zhu L, Castellanos ME, Liu Q, et al
    Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study.
    Clin Infect Dis. 2017 Oct 20. doi: 10.1093.
    PubMed     Abstract available


  207. OSMAN M, Lee K, Du Preez K, Dunbar R, et al
    Excellent Treatment Outcomes in Children Treated for Tuberculosis Under Routine Operational Conditions in Cape Town, South Africa.
    Clin Infect Dis. 2017;65:1444-1452.
    PubMed     Abstract available


  208. VANINO E, Tadolini M, Attard L, Po C, et al
    Systematic Tuberculosis Screening in Asylum Seekers in Italy.
    Clin Infect Dis. 2017;65:1407-1409.
    PubMed     Abstract available


  209. DOBLER CC
    Cumulative Incidence and Incidence Rate Ratio for Estimation of Risk of Tuberculosis in Patients With Cancer.
    Clin Infect Dis. 2017;65:1423.
    PubMed    


  210. FARHAT MR, Jacobson KR, Franke MF, Kaur D, et al
    Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study.
    Clin Infect Dis. 2017;65:1364-1370.
    PubMed     Abstract available


  211. MCKENNA L, Frick M, Lee C, Namutamba D, et al
    A Community Perspective on the Inclusion of Pregnant Women in Tuberculosis Drug Trials.
    Clin Infect Dis. 2017;65:1383-1387.
    PubMed     Abstract available


  212. ADU-GYAMFI CG, Snyman T, Hoffmann CJ, Martinson NA, et al
    Plasma Indoleamine 2, 3-Dioxygenase, a Biomarker for Tuberculosis in Human Immunodeficiency Virus-Infected Patients.
    Clin Infect Dis. 2017;65:1356-1358.
    PubMed     Abstract available


  213. COOKSON ST, Maloney SA
    Keeping Up With a World in Motion: Screening Strategies for Migrating Populations.
    Clin Infect Dis. 2017;65:1410-1411.
    PubMed    


  214. LEE RS, Howden BP
    The Critical Importance of Sampling Fraction to Inferences of Mycobacterium tuberculosis Transmission.
    Clin Infect Dis. 2017 Oct 13. doi: 10.1093.
    PubMed    


    September 2017
  215. LIN HH, Wu CY, Wang CH, Fu H, et al
    Association of obesity, diabetes, and risk of tuberculosis: two population-based cohorts.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Abstract available


  216. SALAZAR-AUSTIN N, Hoffmann J, Cohn S, Mashabela F, et al
    Poor Obstetric and Infant Outcomes in HIV-Infected Pregnant Women with Tuberculosis in South Africa: The Tshepiso Study.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Abstract available


  217. THAO LTP, Heemskerk AD, Geskus RB, Mai NTH, et al
    Prognostic models for 9 month mortality in tuberculous meningitis.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Abstract available


  218. NEMES E, Hesseling AC, Tameris M, Mauff K, et al
    Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin (BCG) for Infants of HIV Infected Mothers: A Phase 2 Randomized Controlled Trial.
    Clin Infect Dis. 2017 Sep 26. doi: 10.1093.
    PubMed     Abstract available


  219. SIVRO A, McKinnon LR, Yende-Zuma N, Gengiah S, et al
    Plasma Cytokine Predictors of Tuberculosis Recurrence in Antiretroviral-Treated Human Immunodeficiency Virus-infected Individuals from Durban, South Africa.
    Clin Infect Dis. 2017;65:819-826.
    PubMed     Abstract available


    August 2017
  220. BACCANI I, Antonelli A, Galano A, Bartalesi F, et al
    Linezolid-resistant Enterococcus faecalis infection following prolonged low-dosage linezolid treatment for multi-drug-resistant tuberculosis.
    Clin Infect Dis. 2017 Aug 20. doi: 10.1093.
    PubMed    


  221. DRANCOURT M
    Please, no more gastric aspirate to diagnose pulmonary tuberculosis in children.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed    


  222. MUNOZ L, Santin M, Alcaide F, Ruiz-Serrano MJ, et al
    QuantiFERON(R)-TB Gold In-Tube as a confirmatory test for tuberculin skin test in tuberculosis contact tracing: A non-inferiority clinical trial.
    Clin Infect Dis. 2017 Aug 18. doi: 10.1093.
    PubMed     Abstract available


  223. ARGUELLO PEREZ E, Seo SK, Schneider WJ, Eisenstein C, et al
    Management of Latent Tuberculosis Infection among Healthcare Workers: 10-year Experience at a Single Center.
    Clin Infect Dis. 2017 Aug 17. doi: 10.1093.
    PubMed     Abstract available


  224. SCHECHTER MC, Bizune D, Kagei M, Machaidze M, et al
    Time to Sputum Culture Conversion and Treatment Outcomes Among Patients with Isoniazid-Resistant Tuberculosis in Atlanta, Georgia.
    Clin Infect Dis. 2017 Aug 3. doi: 10.1093.
    PubMed     Abstract available


    July 2017
  225. SALINAS JL, Armstrong LR, Silk BJ, Haddad MB, et al
    Factors Associated with All-Cause Mortality among Patients with Multidrug-Resistant Tuberculosis - United States, 1993-2013.
    Clin Infect Dis. 2017 Jul 29. doi: 10.1093.
    PubMed     Abstract available


  226. FLORIDIA M, Ciccacci F, Andreotti M, Hassane A, et al
    Tuberculosis case finding with combined rapid point of care assays (Xpert(R) MTB/RIF and LAM) in HIV-positive individuals starting antiretroviral treatment in Mozambique.
    Clin Infect Dis. 2017 Jul 23. doi: 10.1093.
    PubMed     Abstract available


    June 2017
  227. SMITH SE, Pratt R, Trieu L, Barry PM, et al
    Epidemiology of pediatric multidrug-resistant tuberculosis in the United States, 1993-2014.
    Clin Infect Dis. 2017 Jun 19. doi: 10.1093.
    PubMed     Abstract available


  228. MOORE DP, Higdon MM, Hammitt LL, Prosperi C, et al
    The Incremental Value of Repeated Induced Sputum and Gastric Aspirate Samples for the Diagnosis of Pulmonary Tuberculosis in Young Children With Acute Community-Acquired Pneumonia.
    Clin Infect Dis. 2017;64.
    PubMed     Abstract available


  229. ROHLWINK UK, Mauff K, Wilkinson KA, Enslin N, et al
    Biomarkers of cerebral injury and inflammation in pediatric tuberculous meningitis.
    Clin Infect Dis. 2017 Jun 9. doi: 10.1093.
    PubMed     Abstract available


    May 2017
  230. SANDUL AL, Nwana N, Holcombe JM, Lobato MN, et al
    High Rate of Treatment Completion in Program Settings with 12-Dose Weekly Isoniazid and Rifapentine (3HP) for Latent Mycobacterium tuberculosis Infection.
    Clin Infect Dis. 2017 May 30. doi: 10.1093.
    PubMed     Abstract available


  231. FURIN J, Cox H
    To Test or Not to Test? Ending the Age-Old Debate for Drug-Resistant Tuberculosis.
    Clin Infect Dis. 2017 May 26. doi: 10.1093.
    PubMed    


  232. AIBANA O, Franke MF, Huang CC, Galea JT, et al
    Impact of Vitamin A and Carotenoids on the Risk of Tuberculosis Progression.
    Clin Infect Dis. 2017 May 20. doi: 10.1093.
    PubMed     Abstract available


  233. KAWKITINARONG K, Suwanpimolkul G, Kateruttanakul P, Manosuthi W, et al
    Real-Life Clinical Practice of Using the Xpert MTB/RIF Assay in Thailand.
    Clin Infect Dis. 2017;64.
    PubMed     Abstract available


  234. MANSON AL, Abeel T, Galagan JE, Sundaramurthi JC, et al
    Mycobacterium tuberculosis Whole Genome Sequences From Southern India Suggest Novel Resistance Mechanisms and the Need for Region-Specific Diagnostics.
    Clin Infect Dis. 2017 May 12. doi: 10.1093.
    PubMed     Abstract available


  235. HARAUSZ EP, Leigh J, Garcia-Prats AJ, Furin J, et al
    Stability of Second-Line Tuberculosis Medications Mixed with Milk or Yogurt.
    Clin Infect Dis. 2017 May 6. doi: 10.1093.
    PubMed    


  236. SEIFERT M, Georghiou SB, Garfein RS, Catanzaro D, et al
    Impact of fluoroquinolone use on mortality among a cohort of suspected drug-resistant tuberculosis patients.
    Clin Infect Dis. 2017 May 5. doi: 10.1093.
    PubMed     Abstract available


  237. WALKER NF, Wilkinson KA, Meintjes G, Tezera LB, et al
    Matrix Degradation in Human Immunodeficiency Virus Type 1-Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study.
    Clin Infect Dis. 2017 May 5. doi: 10.1093.
    PubMed     Abstract available


  238. HEEMSKERK AD, Nguyen MTH, Dang HTM, Vinh Nguyen CV, et al
    Clinical Outcomes of Patients With Drug-Resistant Tuberculous Meningitis Treated With an Intensified Antituberculosis Regimen.
    Clin Infect Dis. 2017 May 4. doi: 10.1093.
    PubMed     Abstract available


    April 2017
  239. AUNG HL, Nyunt WW, Fong Y, Cook GM, et al
    First two extensively drug-resistant tuberculosis cases from Myanmar treated with bedaquiline.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed    


  240. PHILLIPS PP
    Setting tuberculosis regimen development on a firm foundation.
    Clin Infect Dis. 2017 Apr 10. doi: 10.1093.
    PubMed    


  241. BONNETT LJ, Ken-Dror G, Koh G, Davies GR, et al
    Comparing the efficacy of drug regimens for pulmonary tuberculosis: meta-analysis of endpoints in early phase clinical trials.
    Clin Infect Dis. 2017 Apr 10. doi: 10.1093.
    PubMed     Abstract available


  242. RAOULT D
    Old Antibiotics for Tuberculosis.
    Clin Infect Dis. 2017;64:983.
    PubMed    


  243. BROGER T, Basu Roy R, Filomena A, Greef CH, et al
    Diagnostic Performance of Tuberculosis-Specific IgG Antibody Profiles in Patients with Presumptive Tuberculosis from Two Continents.
    Clin Infect Dis. 2017;64:947-955.
    PubMed     Abstract available


    March 2017
  244. JANSSEN S, Schutz C, Ward A, Nemes E, et al
    Mortality in Severe HIV-TB Associates with Innate Immune Activation and Dysfunction of Monocytes.
    Clin Infect Dis. 2017 Mar 24. doi: 10.1093.
    PubMed     Abstract available


  245. MARKS SM, Mase SR, Bamrah Morris S
    Systematic Review, Meta-Analysis, and Cost Effectiveness of Treatment of Latent Tuberculosis Infection to Reduce Progression to Multidrug-Resistant Tuberculosis.
    Clin Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Abstract available


  246. COLLIER D, Iwuji C, Derache A, de Oliveira T, et al
    Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.
    Clin Infect Dis. 2017 Mar 13. doi: 10.1093.
    PubMed     Abstract available


    February 2017
  247. ROCKWOOD N N, Pasipanodya JG, Denti P, Sirgel F, et al
    Concentration-dependent antagonism and culture conversion in pulmonary tuberculosis.
    Clin Infect Dis. 2017 Feb 16. doi: 10.1093.
    PubMed    


  248. RAVIMOHAN S, Tamuhla N, Nfanyana K, Ni H, et al
    Elevated pre-ART CD39+CD8+ T-cell frequency is associated with early mortality in advanced HIV/TB.
    Clin Infect Dis. 2017 Feb 16. doi: 10.1093.
    PubMed    


  249. COWAN JF, Chandler AS, Kracen E, Park DR, et al
    Clinical Impact and Cost-effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients With Presumptive Pulmonary Tuberculosis in the United States.
    Clin Infect Dis. 2017;64:482-489.
    PubMed    


  250. MARAIS BJ, Heemskerk AD, Marais SS, van Crevel R, et al
    Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies.
    Clin Infect Dis. 2017;64:501-509.
    PubMed    


  251. JOHNSTON JC, Campbell JR, Menzies D
    Effect of intermittency on treatment outcomes in pulmonary tuberculosis: an updated systematic review and meta-analysis.
    Clin Infect Dis. 2017 Feb 14. doi: 10.1093.
    PubMed    


  252. JACOBSON KR, Barnard M, Kleinman MB, Streicher EM, et al
    Implications of failure to routinely diagnose resistance to second-line drugs in patients with rifampicin-resistant tuberculosis on Xpert MTB/RIF: a multisite observational study.
    Clin Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed    


    January 2017
  253. PROANO A, Bravard MA, Lopez JW, Lee GO, et al
    Dynamics of Cough Frequency in Adults Undergoing Treatment for Pulmonary Tuberculosis.
    Clin Infect Dis. 2017 Jan 25. doi: 10.1093.
    PubMed     Abstract available


  254. LEWINSOHN DM, Leonard MK, LoBue PA, Cohn DL, et al
    Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.
    Clin Infect Dis. 2017;64:111-115.
    PubMed     Abstract available


    December 2016
  255. LEE MR, Huang YP, Kuo YT, Luo CH, et al
    Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


  256. CHENG MP, Abou Chakra CN, Yansouni CP, Cnossen S, et al
    Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


  257. CHENG MP, Chakra CN, Yansouni CP, Cnossen S, et al
    Risk of Active Tuberculosis in Patients With Cancer: A Systematic Review and Metaanalysis.
    Clin Infect Dis. 2016 Dec 13. doi: 10.1093.
    PubMed    


  258. COWAN JF, Chandler AS, Kracen E, Park DR, et al
    Clinical Impact and Cost-Effectiveness of Xpert MTB/RIF Testing in Hospitalized Patients with Presumptive Pulmonary Tuberculosis in the United States.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


  259. LEWINSOHN DM, Leonard MK, LoBue PA, Cohn DL, et al
    Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


  260. VINNARD C, King L, Munsiff S, Crossa A, et al
    The Long-Term Mortality of Tuberculosis Meningitis Patients in New York City: A Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


    November 2016
  261. GUMBO T, Makhene MK, Seddon JA
    Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  262. SRIVASTAVA S, Deshpande D, Pasipanodya J, Nuermberger E, et al
    Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  263. DESHPANDE D, Srivastava S, Nuermberger E, Pasipanodya JG, et al
    A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  264. DESHPANDE D, Srivastava S, Nuermberger E, Pasipanodya JG, et al
    Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  265. DESHPANDE D, Srivastava S, Pasipanodya JG, Bush SJ, et al
    Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  266. SRIVASTAVA S, Deshpande D, Pasipanodya JG, Thomas T, et al
    A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  267. SWAMINATHAN S, Pasipanodya JG, Ramachandran G, Hemanth Kumar AK, et al
    Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.
    Clin Infect Dis. 2016;63.
    PubMed     Abstract available


  268. SEDDON JA, Makhene MK
    Harnessing Novel Quantitative Pharmacology Approaches to Optimize the Treatment of Children With Tuberculosis.
    Clin Infect Dis. 2016;63.
    PubMed    


    October 2016
  269. ALFFENAAR JC, Tiberi S, Verbeeck RK, Heysell SK, et al
    Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.
    Clin Infect Dis. 2016.
    PubMed    


  270. NAHID P, Dorman SE, Alipanah N, Barry PM, et al
    Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
    Clin Infect Dis. 2016;63:853-67.
    PubMed     Abstract available


    September 2016
  271. YANG JY, Han M, Koh Y, Kim WS, et al
    Effects of Corticosteroids on Critically Ill Pulmonary Tuberculosis Patients with Acute Respiratory Failure: A Propensity Analysis of Mortality.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


    March 2016
  272. BAHR NC, Marais S, Caws M, van Crevel R, et al
    GeneXpert MTB/Rif to Diagnose Tuberculous Meningitis: Perhaps the First Test but not the Last.
    Clin Infect Dis. 2016.
    PubMed     Abstract available


    January 2016
  273. HSU DC, Faldetta KF, Pei L, Sheikh V, et al
    A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS.
    Clin Infect Dis. 2016;62:258-61.
    PubMed     Abstract available


    December 2015
  274. GUPTA A, Mathad JS, Abdel-Rahman SM, Albano JD, et al
    Towards Earlier Inclusion of Pregnant and Postpartum Women in TB Drug Trials: Consensus Statements from an International Expert Panel.
    Clin Infect Dis. 2015.
    PubMed     Abstract available


    November 2015
  275. RAVIMOHAN S, Tamuhla N, Nfanyana K, Steenhoff AP, et al
    Robust reconstitution of TB-specific polyfunctional CD4+ T-cell responses and rising systemic IL-6 in paradoxical TB-IRIS.
    Clin Infect Dis. 2015.
    PubMed     Abstract available


  276. AKKERMAN OW, Odish OF, Bolhuis MS, de Lange WC, et al
    Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis.
    Clin Infect Dis. 2015.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: